<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               4  CONTRAINDICATIONS<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                        <BR>                           <BR>                              Hypersensitivity to atomoxetine or<BR>other constituents of product. (4.1)<BR>                              <BR>                           <BR>                           <BR>                              STRATTERA use within 2 weeks after discontinuing MAOI<BR>or other drugs that affect brain monoamine concentrations. (4.2,<BR>                                  7.1)<BR>                              <BR>                           <BR>                           <BR>                              Narrow Angle Glaucoma. (4.3)<BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     4.1  Hypersensitivity<BR>                     <BR>                        STRATTERA is<BR>contraindicated in patients known to be hypersensitive to atomoxetine or<BR>other constituents of the product <BR>                              [see Warnings<BR>and Precautions (5.7)]<BR>                           .<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     4.2  Monoamine Oxidase Inhibitors (MAOI)<BR>                     <BR>                        STRATTERA should<BR>not be taken with an MAOI, or within 2 weeks after discontinuing<BR>an MAOI. Treatment with an MAOI should not be initiated within 2 weeks<BR>after discontinuing STRATTERA. With other drugs that affect brain monoamine concentrations, there have been<BR>reports of serious, sometimes fatal reactions (including hyperthermia, rigidity,<BR>myoclonus, autonomic instability with possible rapid fluctuations of vital<BR>signs, and mental status changes that include extreme agitation progressing<BR>to delirium and coma) when taken in combination with an MAOI. Some cases presented<BR>with features resembling neuroleptic malignant syndrome. Such reactions may<BR>occur when these drugs are given concurrently or in close proximity <BR>                              [see<BR>Drug Interactions (7.1)]<BR>                           .<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     4.3  Narrow Angle Glaucoma<BR>                     <BR>                        In clinical trials, STRATTERA use<BR>was associated with an increased risk of mydriasis and therefore its use is<BR>not recommended in patients with narrow angle glaucoma.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>